Volume 2.45 | Nov 14

Pulmonary Cell News 2.45 November 14, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Runx3 Inactivation Is a Crucial Early Event in the Development of Lung Adenocarcinoma
RUNX3 was frequently inactivated in K-RAS mutated human lung adenocarcinomas. A functional genetic screen of a fly mutant library and molecular analysis in cultured cell lines revealed that Runx3 forms a complex with BRD2 in a K-Ras-dependent manner in the early phase of the cell cycle. [Cancer Cell]
Abstract | Full Article | Graphical Abstract | Press Release
PneumaCult™-ALI Medium for Bronchial Epithelial Cells: Watch the Video
 
PUBLICATIONS ( Ranked by impact factor of the journal)
Increased Expression of Bronchial Epithelial Transient Receptor Potential Vanilloid 1 Channels in Patients with Severe Asthma
Scientists examined the molecular, functional, and immunohistochemical expression of transient receptor potential vanilloid 1 (TRPV1) in asthmatic and healthy airways. Cultured primary bronchial epithelial cells from patients with mild asthma, nonasthmatic coughers, and healthy subjects were studied to investigate the functional role of TRPV1. [J Allergy Clin Immunol] Abstract

Anchored PDE4 Regulates Chloride Conductance in Wild-Type and ?F508-CFTR Human Airway Epithelia
Scientists provide evidence that type 4 cyclic nucleotide phosphodiesterases (PDE4s) are critical regulators of the cAMP/PKA-dependent activation of cystic fibrosis transmembrane conductance regulator (CFTR) in primary human bronchial epithelial cells. [FASEB J] Abstract

Loss of Hypoxia-Inducible Factor 2 Alpha (HIF2a) in the Lung Alveolar Epithelium of Mice Leads to Enhanced Eosinophilic Inflammation in Cobalt-Induced Lung Injury
Scientists hypothesized that loss of HIF2a in lung epithelium would provide protection from cobalt-induced inflammation. Mice with HIF2a-deficiency in Club and alveolar type II epithelial cells were exposed to cobalt or saline using a subacute occupational exposure model. [Toxicol Sci] Abstract

Breaking the In-Vitro Alveolar Type II Cell Proliferation Barrier While Retaining Ion Transport Properties
Researchers demonstrated that a novel co-culture technique breaks the in vitro alveolar type II cell proliferation barrier while retaining cell-specific functional properties. [Am J Respir Cell Mol Biol] Abstract

Internalization and Trafficking of Nontypeable Haemophilus influenzae in Human Respiratory Epithelial Cells and the Roles of IgA1 Proteases for Optimal Internalization and Persistence
Researchers showed that nontypeable Haemophilus influenzae invades human bronchial epithelial cells in vitro in a lipid raft- independent manner, is subsequently trafficked via the endolysosomal pathway, and is killed in lysosomes after variable durations of persistence. [Infect Immun] Abstract

LysoTracker Is a Marker of Differentiated Alveolar Type II Cells
LysoTrackerpos alveolar type II (AT2) cells generated SP-Cpos alveolar epithelial cell colonies in culture, and when added to the epithelial colony-forming unit culture medium, LysoTracker marked the differentiation of stem/progenitor-derived AT2 cells. [Respir Res] Abstract | Full Article

LUNG CANCER

Foxm1 Transcription Factor Is Required for the Initiation of Lung Tumorigenesis by Oncogenic KrasG12D
Researchers used transgenic mice expressing KrasG12D under control of Sftpc promoter to demonstrate that Foxm1 was induced in type II epithelial cells before the formation of lung tumors. [Oncogene] Abstract

Glycogen Synthase Kinase 3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
Consistently, in determining tivantinib’s activity profile in a broad panel of non-small cell lung cancer cell lines, scientists found that, in contrast to several more potent c-MET inhibitors, tivantinib reduces cell viability across most of these cell lines. [ACS Chem Biol] Abstract

Sequential Targeted Delivery of Pacilitaxel and Camptothecin Using a Crosslinked ‘Nanosponge’ Network for Lung Cancer Chemotherapy
Researchers showed significant G2/M phase cell cycle arrest, changes in microtubule dynamics that produced increased apoptotic cell death and decreased proliferation with initial exposure to nanoparticle (NP) paclitaxel followed by NP camptothecin in lung cancer cells. [Mol Pharm] Abstract

Extract of Bryophyllum laetivirens Reverses Etoposide Resistance in Human Lung A549 Cancer Cells by Downregulation of NF-?B
Researchers attempted to identify a new and effective anticancer drug against multidrug resistant cancer cells. They first found that lung cancer A549 cells resistant to etoposide exhibit upregulation of NF-?B and SIRT1 in comparison to A549 parental cells. [Oncol Rep] Abstract

View On-Demand Webinar: Optimized Differentiation of Bronchial Epithelial Cells
 
REVIEWS
Prevention of Asthma: Where Are We in the 21st Century?
The authors review multiple environmental, biologic and sociologic factors that may be important in the development of asthma. Meta-analyses of studies have demonstrated that multifaceted interventions are required in order to develop asthma prevention. [Expert Rev Clin Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
UbiVac announced the results of a Phase I clinical trial and the initiation of a Phase II clinical trial of its first-in-class autophagosome DRibble vaccine, DPV-001. [PR Newswire Association LLC] Press Release

Foundation Medicine Partners with Broad-Based Coalition to Advance Revolutionary New Clinical Trial Design in Lung Cancer
Foundation Medicine, Inc. announced that it has partnered with Friends of Cancer Research, as well as federal health and regulatory agencies, pharmaceutical companies, multiple cooperative groups and patient advocacy organizations to develop the clinical trial design for the “Master Protocol” study in patients with squamous cell carcinoma of the lung. [Foundation Medicine, Inc.] Press Release

Discovery Labs Receives FDA Clearance of IND to Initiate AEROSURF® Phase II Clinical Program
Discovery Laboratories, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s investigational new drug (IND) application for AEROSURF® and the Company can initiate its Phase II clinical program. [Discovery Laboratories, Inc.] Press Release

Boehringer Ingelheim Submits Applications in Europe to Extend the Indication for the Use of Tiotropium Respimat® to the Treatment of Asthma in Adults Aged 18 Years and Over
Boehringer Ingelheim announced submission of applications to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over. [Boehringer Ingelheim GmbH] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW ISREC Symposium 2014: Metastatic Colonization
January 22-25, 2014
Crans Montana, Switzerland

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Research Fellow – Influence of the Lung Microbiome on Host Immune Response to Respiratory Pathogens (Queen’s University Belfast)

Postdoctoral Fellow – Respiratory Research (Karolinska Institutet)

PhD Studentship – Epithelial Surfaces in the Lung (University of East Anglia)

Postdoctoral Scientist – Prognostic Biomarkers in Lung Cancer and Mesothelioma (Medical Research Council)

Postdoctoral Research Fellow – Emphysema (University College Dublin)

Postdoctoral Research Associate – Airway Innate Defense and Biology (University of North Carolina – Chapel Hill)

Senior Postdoctoral Fellow – Mechanisms of Lung Injuries (University of Texas Health Science Center at Tyler)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Pulmonary Cell News: Archives | Events | Contact Us